Breast Cancer Clinical Trial
Official title:
DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation
1.1. Primary Objectives
- To determine if MRI DWIBS can accurately identify suspicious lesions previously
categorized on mammography and sonography as potentially malignant.
- We will also validate whether DWIBS-MRI ADC values can be used to accurately
differentiate benign from malignant lesions. Additionally, because it is not known
whether tumor type or growth rate (Ki67 values) will affect our results, we will include
these parameters in our analysis.
- Once we validate the use of DWIBS-MRI ADC values to determine malignancy, can we
establish an ADC threshold value to decrease the number of false positive biopsies that
are performed while still maintaining a zero false negative rate?
- This study will also assess the correlation between ADC values and the Ki-67
proliferative index of malignant lesions.
n/a
NCT number | NCT04491864 |
Study type | Observational |
Source | Baylor Research Institute |
Contact | Mariana Hurutado, RN |
Phone | 214.820.7755 |
[email protected] | |
Status | Recruiting |
Phase | |
Start date | March 11, 2019 |
Completion date | March 11, 2024 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
|
||
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Enrolling by invitation |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Recruiting |
NCT04190381 -
A Study to Evaluate the Safety and Clinical Outcome of Using FR-Mask in Breast Cancer Patients With Radiation-irritated Skin After Radiotherapy
|
N/A | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT02894398 -
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
|
Phase 2 | |
Completed |
NCT01857193 -
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
|
Phase 1 |